REG - Oncimmune Hldngs PLC - Director/PDMR Shareholding

Oncimmune HoldingsAnnouncement

24/04/2020 16:00

RNS Number : 8568K
  
Oncimmune Holdings PLC
  
24 April 2020
  
 

Oncimmune Holdings plc
 
("Oncimmune" or the "Company")
 
Director/PDMR's Dealing
 
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, announces the following dealings in the Company's ordinary shares of £0.01 each in the Company ("Ordinary Shares") by Adam Hill, Chief Executive Officer and Matthew Hall, Chief Financial Officer.
 



Director/PDMR


Date of purchase


Number of shares purchased


Purchase price


Total Shares held


% ISC held following purchase




Adam Hill


24 April 2020


11,111


£0.90


32,432


0.05%




Matthew Hall


24 April 2020


1,176


£0.85


10,663


0.02%



 
 
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
 





 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 


Adam Hill




2
 


Reason for the notification




a)
 


Position/status
 


Chief Executive Officer




b)
 


Initial notification /Amendment
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 


Oncimmune Holdings plc




b)
 


LEI


213800HCYIWT6YPI1I02 




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument


Ordinary Shares of £0.01 each
 














Identification code


ISIN: GB00BYQ94H38














b)
 


Nature of the transaction
 


Purchase of shares




c)
 


Price(s) and volume(s)




























Price


Volume
















£0.90


11,111






























d)
 


Aggregated information


















- Aggregated volume


Same as above














- Price


















e)
 


Date of the transaction
 


24 April 2020




f)
 


Place of the transaction


London stock exchange, AIM




















 


Details of the person discharging managerial responsibilities / person closely associated
 




a)
 


Name
 


Matthew Hall




2
 


Reason for the notification




a)
 


Position/status
 


Chief Financial Officer




b)
 


Initial notification /Amendment
 


Initial notification




3
 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 




a)
 


Name
 


Oncimmune Holdings plc




b)
 


LEI


213800HCYIWT6YPI1I02 




4
 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)
 


Description of the financial instrument, type of instrument


Ordinary Shares of £0.01 each
 














Identification code


ISIN: GB00BYQ94H38














b)
 


Nature of the transaction
 


Purchase of shares




c)
 


Price(s) and volume(s)




























Price


Volume
















£0.85


1,176






























d)
 


Aggregated information


















- Aggregated volume


Same as above














- Price


















e)
 


Date of the transaction
 


24 April 2020




f)
 


Place of the transaction


London stock exchange, AIM



 
 
For further information:
 
Oncimmune Holdings plc
 
Ron Kirschner, General Counsel and Company Secretary
 
contact@oncimmune.com    
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHBSGDSUUDDGGS